Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MCLA-145 in Participants With Advanced or Metastatic Malignancies

NCT03922204 is registered in ClinicalTrials.gov with Merus B.V. as lead sponsor.

NCT NCT03922204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03922204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MCLA-145 in Participants With Advanced or Metastatic Malignancies
Lead sponsor
Merus B.V.
Phase
Phase 1
Overall status
Completed
Start date
May 8, 2019
Completion date
November 7, 2024
Enrollment
72 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, b-cell lymphoma, adult, solid tumor, adult